A recent study examined whether the use of the anti–tumor necrosis factor agent infliximab could reduce the death of photoreceptors after retinal detachment in an experimental mouse model.
Tumor necrosis factor-alpha (TNF-a) participates in photoreceptor cell death, a process involved in many retinal diseases, including retinal detachment (RD), that can cause irreversible visual impairment and blindness. The death of photoreceptor cells begins immediately after RD, peaking at 2 to 3 days after RD. A recent study, published in Scientific Reports, examined whether the use of the anti-TNF agent infliximab could reduce the death of photoreceptors after RD in an experimental mouse model.
First, the researchers induced RD in adult male mice, and detected the expression of the TNF-a protein in the retina at 1 day, 3 days, and 7 days after RD using Western blotting and immunofluorescence testing. Analysis showed that the expression of TNF-a in the retina peaked in photoreceptor cells at 1 day after RD.
Next, the researchers investigated the effects of the anti-TNF agent infliximab on the expression of TNF-a following RD. The investigators injected infliximab (5 mg/kg) intraperitoneally 2 hours before RD induction, and injected saline into controls. Retinas were harvested and sectioned at 1 day following RD. The researchers found that the expression of TNF-a was suppressed after RD in the infliximab-treated retinas compared with the control retinas at days 1, 3, and 7.
Additionally, the investigators sought to better understand whether infliximab could regulate autophagy, which plays a dual role in cell death and cell survival, by examining the impact of infliximab on the activity of 2 proteins associated with autophagy: LC3B and Atg5. The researchers found that, with infliximab treatment, increased expression of LC3B was maintained through 7 days after RD, while the level of LC3B decreased to baseline at 7 days after RD without infliximab. Similarly, expression of Atg5 increased at day 1 to day 3, and its expression was sustained at 7 days with infliximab. Atg5 levels also declined to baseline at 7 days following RD in controls.
To examine whether this prolonged autophagy caused by inhibiting TNF-a with infliximab led to increased cell survival in photoreceptors, the researchers investigated photoreceptor cell survival at 7 days after RD with infliximab, and found that, with infliximab treatment, there was not a decrease in the number of photoreceptor cells in the outer nuclear layer of the retina, compared with a 40% to 50% loss of such cells in retinas not treated with infliximab.
The researchers concluded that TNF-a is a critical regulator of autophagy that is correlated closely to the homeostasis of photoreceptor cells in this experimental mouse model.
“Autophagy was thought to have a complex influence on cell death and cell survival. We proved that the appropriate level of autophagy activity had a critical influence on the augmentation of cell survival,” the authors concluded. "Control of autophagy to a proper level under pathological conditions may provide a new therapeutic approach to treat photoreceptor degeneration in retinal disorders."
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.